How many drugs treat Rectal cancer with wild-type RAS?

Drug Landscape tracks 2 marketed treatments for Rectal cancer with wild-type RAS (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/rectal-cancer-with-wild-type-ras.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rectal cancer with wild-type RAS — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rectal cancer with wild-type RAS (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Rectal cancer with wild-type RAS, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Erbitux	cetuximab	Imclone	Epidermal Growth Factor Receptor Antagonist [EPC]	Epidermal growth factor receptor		2004-01-01
Erbitux	Erbitux	Hellenic Oncology Research Group		Epidermal growth factor receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Hellenic Oncology Research Group · 1 drug in Rectal cancer with wild-type RAS
Imclone · 1 drug in Rectal cancer with wild-type RAS

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Rectal cancer with wild-type RAS:

Cite this brief

Drug Landscape (2026). Rectal cancer with wild-type RAS — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/rectal-cancer-with-wild-type-ras. Accessed 2026-06-10.

Rectal cancer with wild-type RAS full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing